Anebulo Pharmaceuticals, Inc.
ANEB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 2.82 | -0.25 | 0.10 | -0.81 |
| FCF Yield | -1.24% | -2.79% | -4.49% | -3.05% |
| EV / EBITDA | -40.86 | -22.34 | 48.50 | -12.92 |
| Quality | ||||
| ROIC | -22.39% | -19.99% | -14.05% | -17.30% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.59 | 0.77 | 0.96 | 0.57 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 22.94% | -3.13% | -13.95% | 16.82% |
| Safety | ||||
| Net Debt / EBITDA | 4.58 | 5.47 | -28.81 | 6.24 |
| Interest Coverage | -129.61 | -133.66 | -7.72 | -43.35 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |